MDM2 Gene Amplification and Expression in Non-Small Cell Lung Cancer
Author Information
Author(s): M Higashiyama, O Doi, K Kodama, H Yokouchi, T Kasugai, S Ishiguro, K Takami, T Nakayama, I Nishisho
Primary Institution: Osaka Medical Center for Cancer and Cardiovascular Diseases
Hypothesis
What is the clinicopathological and prognostic value of MDM2 abnormalities in non-small-cell lung cancer?
Conclusion
MDM2 protein expression is a favorable prognostic marker, especially among patients without p53 protein accumulation.
Supporting Evidence
- MDM2 gene amplification was detected in only 2 (7%) of the 30 tested patients.
- MDM2 protein was found in 48 (24%) of the 201 patients.
- MDM2-positive patients tended to have a better prognosis (P = 0.062).
- Among p53-negative patients, those with positive MDM2 expression showed significantly better prognosis (P = 0.039).
Takeaway
This study found that a protein called MDM2 can help doctors predict how well patients with lung cancer might do, especially if they don't have another protein called p53.
Methodology
MDM2 gene amplification and protein expression were analyzed in surgically resected non-small-cell lung cancer samples using immunohistochemistry and Southern blot analysis.
Limitations
The study had a relatively small sample size for MDM2 gene amplification analysis.
Participant Demographics
Of the 201 patients, 146 were men and 48 were women, aged between 35 and 83 years (mean 63.4 years).
Statistical Information
P-Value
P = 0.039
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website